Corneal collagen crosslinking with riboflavin and ultraviolet A to treat induced keratectasia after laser in situ keratomileusis

Farhad Hafezi, MD, John Kanellopoulos, MD, Rainer Wiltfang, MD, Theo Seiler, MD, PhD

PURPOSE: To determine whether riboflavin and ultraviolet-A (UVA) corneal crosslinking can be used as an alternative therapy to prevent the progression of keratectasia.

SETTING: Institute for Refractive and Ophthalmic Surgery, Zurich, Switzerland, and a private clinic, Athens, Greece.

METHODS: Corneal crosslinking was performed in 10 patients with formerly undiagnosed forme fruste keratoconus or pellucid marginal corneal degeneration who had laser in situ keratomileusis (LASIK) for myopic astigmatism and subsequently developed iatrogenic keratectasia. Surgery was performed in 1 eye per patient.

RESULTS: Crosslinking induced by riboflavin and UVA arrested and/or partially reversed keratectasia over a postoperative follow-up of up to 25 months as demonstrated by preoperative and postoperative corneal topography and a reduction in maximum keratometric readings.

CONCLUSION: Riboflavin–UVA corneal crosslinking increased the biomechanical stability of the cornea and may thus be a therapeutic means to arrest and partially reverse the progression of LASIK-induced iatrogenic keratectasia.


Since its first description in 1998, iatrogenic keratectasia induced by laser in situ keratomileusis (LASIK) was quickly recognized as a major complication of corneal refractive laser surgery.1,2 Affected eyes have progressive central or inferior corneal steepening associated with stromal thinning and significant changes in refractive error. The major risk factors for keratectasia after LASIK surgery are a low residual stromal thickness (RST), retreatments, and preexisting abnormal corneal topography.3,4 Until recently, treatment options were limited. In addition to rigid contact lenses, insertion of intrastromal rings might help mechanically stabilize the cornea.5,6 However, most cases are treated by penetrating keratoplasty (PKP).7

Riboflavin and ultraviolet-A (UVA) crosslinking of corneal collagen is a new method to increase the biomechanical stability of the cornea by inducing additional crosslinks between or within collagen fibers using UVA light and riboflavin as photomediators.8 Its therapeutic potential for the treatment of progressive keratoconus was shown in a clinical phase I study.9

Recently, Kohlhaas et al.10 reported a case of iatrogenic keratectasia after LASIK that was successfully treated by crosslinking. We report the application of this method in a series of cases with a follow-up period of up to 25 months.

PATIENTS AND METHODS

Patient Cohort

This study comprised 10 patients who had LASIK at different locations and were referred to 2 centers (4 to Institute
for Refractive and Ophthalmic Surgery, Zurich, Switzerland; 6 to LaserVision, Athens, Greece). The patients were contact lens intolerant or refused to wear contact lenses. All patients had signs of progressive induced keratocasias with maximum keratometric (K) readings of 60.0 diopters (D) and a central corneal thickness (CCT) by optical and ultrasonic pachymetry of at least 400 μm. Inclusion criteria were identification of progressive keratocasia in corneal topographies using the increase in maximum K readings in several consecutive recordings over a period of up to 3 months and changes in refraction reported by the patient, referring physician, or both. Crosslinking was performed in 1 eye of each patient.

### Examination

The preoperative and postoperative examinations included slitlamp evaluation; best spectacle-corrected visual acuity (BSCVA) with and without pinhole; corneal topography and Scheimplug imaging, including corneal thickness at the thinnest point (Pentacam, Oculus Instruments); ultrasonic pachymetry (Tomey) of the central cornea; and Goldmann applanation tonometry. Three consecutive measurements were taken for corneal topography, Scheimplug analysis, and pachymetry. For corneal topography, the measurement with the highest K value was chosen and for ultrasonic pachymetry, the thinnest measurement was chosen. (Each single measurement represents the mean of 5 consecutive measurements.)

### Surgical Technique

The surgical technique has been described. After topical anesthesia of tetracaine 1% and oxybuprocazone 0.4% eye drops was administered, the corneal epithelium was mechanically removed within a 8.0 mm diameter exclusively.

Next, riboflavin (0.1% solution 10 mg riboflavin-5-phosphate in 10 mL dextran-T-500 20% solution) was applied every 3 minutes for approximately 30 minutes until the stroma was completely penetrated and aqueous was stained yellow (riboflavin shielding). Ultraviolet-A irradiation was accomplished using a commercially available UVA system (UV-X, Peschke Meditrade) with Koeheier optics. Before treatment, the intended 3 mW/cm² surface irradiance (5.4 J/cm² surface dose after 30 minutes) was calibrated using a UVA meter (LaserMate-Q, LASER 2000) at a working distance of 10 cm. During treatment, riboflavin solution was applied every 5 minutes to ensure saturation and balanced salt solution (BSS) was applied every 2 minutes to moisten the cornea.

After the treatment, a contact lens (Acuvue, Johnson & Johnson) soaked in preservative-free ofloxacin 0.3% (Floval SDU) was applied for 72 hours until the epithelium completely healed. This was followed by application of fluorometholone 0.1% eye drops (FMI Liquid) twice daily for 6 weeks.

### RESULTS

Four patients were men, and 6 were women. The mean age was 36.2 years (range 27 to 43 years).

Table 1 shows the preoperative and postoperative findings in all patients. The reason for the biomechanical instability after LASIK was formerly undiagnosed forme fruste keratoconus in 7 cases, undiagnosed pellucid marginal degeneration (PMD) in 1 case, and high correction with a residual corneal thickness of 360 μm in 1 case; the cause could not be identified in 1 patient.

The surgery and postoperative period were uneventful except in 1 case, in which there was endothelial irregularity and some endothelial opacity. The endothelium cleared and had a normal cell count (2350 cells/mm²) 12 months after crosslinking. In the early postoperative period, all eyes had corneal haze comparable to the subepithelial haze after photorefractive keratotomy. The haze was not subepithelial, however. Rather, it was visible in the anterior stroma up to 80% of stromal thickness. Twelve months after crosslinking, all corneas were clear.

Preoperatively, the CCT determined by Pentacam was virtually identical to the ultrasound readings.
Table 1 (Cont.)

<table>
<thead>
<tr>
<th>Fu (Mo)</th>
<th>Optical Pachy (µm)</th>
<th>Ultrasound Pachy (µm)</th>
<th>Maximum K Reading (D)</th>
<th>BSCVA</th>
<th>Sph</th>
<th>Cyl</th>
<th>Axis</th>
</tr>
</thead>
<tbody>
<tr>
<td>25</td>
<td>600</td>
<td>610</td>
<td>56.3</td>
<td>20/25</td>
<td>1.25</td>
<td>-2.3</td>
<td>100</td>
</tr>
<tr>
<td>12</td>
<td>385</td>
<td>410</td>
<td>49.6</td>
<td>20/20</td>
<td>0</td>
<td>-1.0</td>
<td>60</td>
</tr>
<tr>
<td>12</td>
<td>350</td>
<td>410</td>
<td>57.3</td>
<td>20/100</td>
<td>-8</td>
<td>-4.0</td>
<td>110</td>
</tr>
<tr>
<td>12</td>
<td>400</td>
<td>420</td>
<td>50.2</td>
<td>20/30</td>
<td>-1</td>
<td>-2.5</td>
<td>110</td>
</tr>
<tr>
<td>17</td>
<td>400</td>
<td>440</td>
<td>48.8</td>
<td>20/30</td>
<td>0.5</td>
<td>-1.5</td>
<td>115</td>
</tr>
<tr>
<td>21</td>
<td>410</td>
<td>400</td>
<td>53.9</td>
<td>20/40</td>
<td>-4</td>
<td>-3.5</td>
<td>115</td>
</tr>
<tr>
<td>20</td>
<td>410</td>
<td>430</td>
<td>55.6</td>
<td>20/50</td>
<td>-5.5</td>
<td>-3.4</td>
<td>110</td>
</tr>
<tr>
<td>25</td>
<td>460</td>
<td>500</td>
<td>59.1</td>
<td>20/25</td>
<td>-1.75</td>
<td>-2.3</td>
<td>115</td>
</tr>
<tr>
<td>23</td>
<td>450</td>
<td>480</td>
<td>48.3</td>
<td>20/50</td>
<td>-3.75</td>
<td>-3.3</td>
<td>80</td>
</tr>
<tr>
<td>17</td>
<td>420</td>
<td>440</td>
<td>47.1</td>
<td>20/25</td>
<td>-3.75</td>
<td>-2.3</td>
<td>85</td>
</tr>
</tbody>
</table>

Postoperatively, optical pachymetry yielded smaller values than ultrasound pachymetry.

In most cases, BSCVA improved, cylinder decreased, and the corneal optics were more regular. In all cases, there was a reduction in the maximum K readings 12 months after crosslinking. Based on the poor reproducibility of the maximum K readings, a difference between preoperative and postoperative values of 2.0 D or more was considered clinically meaningful, which was the case in 5 of the 10 eyes.

**Case Reports**

Following are 2 case reports. In Case 1, LASIK iatrogenic keratectasia developed after LASIK in an eye with preoperatively unrecognized forme fruste or slowly progressive PMD. In Case 2, bilateral keratectasia occurred after LASIK in an eye without an apparent preoperative ectatic disorder.

**Case 1** A 32-year-old man presented in 2004 with a history of LASIK in the left eye for myopic astigmatism in April 2003. The initial central corneal pachymetry in that eye was 617 µm, the uncorrected visual acuity (UCVA) was 20/60, and the BSCVA was 20/16 with −2.50 − 0.75 × 82. Corneal topography (axial representation) showed signs of forme fruste PMD that was not recognized by the surgeon at that time (Figure 1, A). On the first postoperative day, vision was markedly decreased and the patient decided to postpone surgery in the fellow eye.

At the initial examination at presentation in February 2004, 10 months after the primary surgery, the left eye had a UCVA of 20/400, a BSCVA of 20/60, and corneal thickness of 610 µm. Slitlamp examination revealed a normal state after LASIK. Corneal topography showed a decentered ablation with marked inferior steepening (maximum K reading 55.5 D) consistent with the diagnosis of iatrogenic keratectasia after LASIK (Figure 1, B).

Over the following 3 months, distinct progression of keratectasia was observed in the left eye. The maximum K reading was 57.40 D in May 2004 (Figure 1, C). As PKP was the only valuable therapeutic alternative, the patient was offered riboflavin-UVA crosslinking as a treatment option. Informed consent was obtained after the nature of the procedure and its known risks were explained. During the 25 months after treatment, corneal topography of the left eye showed continuous regression of the maximum K readings (Figures 1, D, and 2). The BSCVA 25 months after treatment was 20/25.

**Case 2** Bilateral keratectasia (Figure 3, A and C) developed 1 year after LASIK with slow progression in both eyes. Crosslinking was performed in the left, nondominant eye. Preoperative CCT by ultrasonic pachymetry was 400 µm. Two weeks after treatment, localized endothelial damage of approximately 0.75 mm × 0.75 mm was noted, along with stromal edema in the central deep cornea exactly below the corneal apex, corresponding to the area of the greatest steepness. The stromal edema slowly resolved during the following 6 weeks. Seven months after treatment, corneal topography of the left eye showed a significant decrease in central corneal steepening (Figure 3, D); corneal steepening remained unchanged in the right eye (Figure 3, B). At 9 months, the central irregular endothelium had cleared and the endothelial cell count was 2350 cells/mm² with mild polymorphism. A preoperative endothelial cell count was not available in
this case, and the endothelial cell count in the fellow eye was 2600 cells/mm².

DISCUSSION
Although LASIK has become increasingly safe and predictable in the past 10 years, induced keratectasia remains a rare but serious complication for which the underlying reasons are not fully understood. Therefore, a new therapeutic means to handle a complication of such severity after elective surgery would be beneficial. Clearly, prevention of induced keratectasia is the better strategy and special emphasis should be placed on recognizing corneas that are at risk before surgery. Reduction of corneal biomechanical strength seems to be an essential element in the chain of events leading to iatrogenic keratectasia after LASIK.
The anterior stroma confers more biomechanical strength to the cornea than the posterior stroma, and it is the anterior stroma that is weakened by flap generation and tissue ablation in LASIK surgery (Park D, et al. IOVS 1995; 36:ARVO Abstract 186). It would therefore be of great clinical value to have a tool to determine the individual biomechanical strength of a cornea preoperatively. Such a tool would enable us to detect corneas at risk preoperatively. Unfortunately, such a technique is not available; however, promising approaches are being studied. These include determination of corneal hysteresis using an ocular response analyzer or interferometric measurements.12,13

Several factors and coefficients can be used to determine the extent of keratectasia. To document progression or regression, parameters such as elevation maps (ie, the so-called anterior or posterior float) would be a valuable alternative. However, preoperative Scheimpflug analysis was not available for most of our patients because the initial LASIK procedure was performed years ago when Scheimpflug imaging was rarely available. In contrast, the maximum K reading is a parameter that is easily accessible to all corneal surgeons because topography measurements have been routinely available for many years. Therefore, and in view of the distinct reduction of ectasia in the cases presented here, we believe that maximum K readings are a valuable tool in characterizing keratectasia, although the reproducibility of this parameter is limited. To improve reproducibility, we performed 3 measurements and chose the highest of the 3 maximum K readings.

Our results show that riboflavin-UVA corneal crosslinking can arrest and, in some cases, partially reverse otherwise progressive iatrogenic keratectasia after LASIK. The observed reduction in maximum K values was probably the result of the increased biomechanical stability of the cornea after crosslinking and is in line with findings in primary keratoconus patients treated similarly.10 After crosslinking in primary keratoconus, Caporossi et al.14 found a trend toward a more regular cornea that is accompanied by an increase in BSCVA. This effect was also found in our patients, but to a larger degree. Four of the 10 eyes gained more than 2 lines in the BSCVA. The cause of this optical regularization is unknown.

Metalloproteinases and other enzymes involved in inflammatory processes may play a role in the pathogenesis of keratoconus.15 It has not been shown that these components also play a role in iatrogenic keratectasia. One might speculate that crosslinking-induced inflammation, including enzymatic degradation of collagen, leads to deterioration. On the other hand, Spoerl et al.16 report that crosslinked collagen is significantly more resistant to enzymatic degradation than native corneal collagen. Perhaps the biochemical stabilization of collagen by crosslinking contributes to the effect.

Our preliminary results show at least middle-term efficacy of the technique. Twelve months after crosslinking, the preoperatively progressive keratectasia was halted (n = 5) or had regressed (n = 5). However, as with any new surgical technique, safety is a concern.

Spoerl et al.17 clearly show that the UVA intensity used during crosslinking is far below the damage threshold for the corneal endothelium, iris, lens, and retina. The structures at greatest risk for damage from the induced radicals are the keratocytes and corneal endothelium. Indeed, keratocytes show apoptosis after crosslinking as deep as 320 μm.18 As long as the corneal stroma is at least 400 μm thick and the irradiance is 3 mW/cm² or less, the endothelium is protected by the riboflavin concentration in the stroma (riboflavin shielding).17 Hot spots in the illumination area or corneas that are too thin may risk damage to the endothelium.

In Case 2, where localized endothelial damage after crosslinking was observed, CCT was 400 μm including the epithelium. Stromal thickness may have been as low as 350 μm, thus too thin to protect the endothelium. In retrospect, it would have been better to increase stromal thickness to 400 μm by swelling using riboflavin solution without dextran after epithelium debridement.

A major factor predisposing to LASIK-induced keratectasia is unrecognized thinning corneal disorders such as keratoconus or PMD, including forme fruste and early stage. In both conditions, altered collagen orientation and structure decrease the biomechanical strength of the tissue.19,20 There is general agreement that corneal thinning disorders are a contraindication to LASIK.1 Although various indices to detect ectatic disorders in corneal topography have been proposed,21,22 identification of forme fruste keratoconus or PMD remains difficult in some cases.

Other factors include retreatments, thin corneas, and a low RST caused by generation of thick flaps or excessive tissue ablation.3,4,23–26 Some authors suggest that an absolute RST of at least 250 μm should always be respected; others suggest that the risk for ectasia occurs when the ablation reduces corneal thickness to 55% or more of the preoperative values1,2,23,24 or that the minimum corneal thickness might be specific to the individual eye.3 In some cases of iatrogenic keratectasia, even postoperative cases, the reason for the keratectasia remains unclear and we must assume decreased, but asymptomatic, biomechanical strength, as we describe in Case 2.

The treatment of iatrogenic keratectasia after LASIK has been rigid contact lenses and if contact lenses are
not tolerated or the ectatic process is progressive, penetrating or deep lamellar keratoplasty. At this stage of clinical knowledge about corneal crosslinking, we recommend using it as a minimally invasive alternative to keratoplasty in patients who are contact lens-intolerant. After crosslinking, penetrating or deep lamellar keratoplasty remains a therapeutic option. In this paper, we show the feasibility of corneal crosslinking to arrest progressive keratectasia after LASIK surgery. After more clinical information on the safety and efficacy of the method is available, the strategy may change significantly. Under such circumstances, crosslinking might be performed as early as possible to prevent a further decrease in BSCVA.

In conclusion, riboflavin–UVA corneal crosslinking increased the biomechanical and biochemical stability of the cornea and may thus be a therapeutic means to arrest or reverse the progression of LASIK-induced keratectasia. It is common clinical knowledge that keratoconus progresses independent of whether rigid contact lenses are used. Similarly, to our knowledge, no scientific information is available on whether rigid contact lenses can arrest iatrogenic keratectasia after LASIK. Although we included only contact lens-intolerant patients in our study, based on our findings, we believe crosslinking should be performed in all patients with progressive iatrogenic keratectasia, even if they can tolerate contact lenses. Further studies should include more patients and a longer follow-up to verify the permanency of the induced effects as well as the safety of crosslinking.

REFERENCES